Therefore, although it still remains to be determined whether the EGFR suppression by VNR itself may lead to a better antitumor effect of VNR in EGFR-mutated lung adenocarcinoma, it is possible that this synergism also contributed to the favorable antitumor activity observed in patients treated with VNR + DIF. This evidence concerns the gene EGFR and lung adenocarcinoma.